![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, July 19, 2014 12:59:48 AM
Quote:
"Amarantus has been working alongside Beckman-Coulter, a labotatory diagnostics supply company. It is rumored that an acquisition of AMBS by Beckman-Coulter is a possibility, given the clinical success of LymPro. Beckman-Coulter appears to have the finances, ability, and incentive to do so.
Beckman-Coulter greatly increased the efficiency of the diagnostic Complete Blood Count. At the time, the Coulter method swept laboratories across the world, given that it automated a test which otherwise had to be manually counted by lab technicians.
"
End Quote
Ref:
https://stockwiki.org/index.php/Ambs
Disclaimer
I do not proclaim that this is true or accurate,
I found it on the internet and I have no idea
whether its true or false. I would error on false
because buyout rumors are not very accurate.
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM